[{"id":"78b1d8da-ee62-4e5e-a188-4a012d565c96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06863402","created_at":"2025-07-19T13:20:16.362Z","updated_at":"2025-07-19T13:20:16.362Z","phase":"Phase 2","brief_title":"Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype","source_id_and_acronym":"NCT06863402","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • nemtabrutinib (MK-1026)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2030","study_completion_date":" 04/01/2030","last_update_posted":"2025-07-18"},{"id":"814f07a4-6ae3-424e-b8de-ef7b7143e4c7","acronym":"BELLWAVE-010","url":"https://clinicaltrials.gov/study/NCT05947851","created_at":"2023-07-17T14:08:45.600Z","updated_at":"2025-02-25T15:28:11.395Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","source_id_and_acronym":"NCT05947851 - BELLWAVE-010","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • BTK • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • BTK • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 06/27/2033","primary_completion_date":" 06/27/2033","study_txt":" Completion: 06/27/2033","study_completion_date":" 06/27/2033","last_update_posted":"2025-02-11"},{"id":"63e0d60a-e16f-4451-bd50-7c30a33e2a8d","acronym":"BELLWAVE-008","url":"https://clinicaltrials.gov/study/NCT05624554","created_at":"2022-11-22T15:58:55.794Z","updated_at":"2024-07-02T16:34:25.934Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","source_id_and_acronym":"NCT05624554 - BELLWAVE-008","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • Truxima (rituximab-abbs) • fludarabine IV • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/16/2023","start_date":" 03/16/2023","primary_txt":" Primary completion: 05/19/2027","primary_completion_date":" 05/19/2027","study_txt":" Completion: 03/17/2031","study_completion_date":" 03/17/2031","last_update_posted":"2024-06-14"},{"id":"573d49f4-aa69-4732-80f5-94630ed62694","acronym":"BELLWAVE-003","url":"https://clinicaltrials.gov/study/NCT04728893","created_at":"2021-01-28T12:53:09.367Z","updated_at":"2024-07-02T16:34:37.168Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)","source_id_and_acronym":"NCT04728893 - BELLWAVE-003","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • CCND1 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr t(11;14) • CCND1 overexpression","tags":["TP53 • CCND1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr t(11;14) • CCND1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 490","initiation":"Initiation: 04/05/2021","start_date":" 04/05/2021","primary_txt":" Primary completion: 03/19/2027","primary_completion_date":" 03/19/2027","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2024-06-07"},{"id":"88f42f2b-3280-4f89-8f51-0e7028896643","acronym":"BELLWAVE-001","url":"https://clinicaltrials.gov/study/NCT03162536","created_at":"2021-01-18T15:35:37.913Z","updated_at":"2024-07-02T16:35:15.719Z","phase":"Phase 1/2","brief_title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","source_id_and_acronym":"NCT03162536 - BELLWAVE-001","lead_sponsor":"ArQule, Inc., a subsidiary of Merck Sharp \u0026 Dohme LLC, a subsidiary of Merck \u0026 Co., Inc. (Rahway, NJ USA)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BTK mutation • BCL6 translocation • BTK C481","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BTK mutation • BCL6 translocation • BTK C481"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nemtabrutinib (MK-1026)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 06/26/2017","start_date":" 06/26/2017","primary_txt":" Primary completion: 09/12/2025","primary_completion_date":" 09/12/2025","study_txt":" Completion: 09/12/2025","study_completion_date":" 09/12/2025","last_update_posted":"2024-03-08"}]